Literature DB >> 3949241

Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.

P Gomes, C du Boulay, C L Smith, G Holdstock.   

Abstract

The Crohn's disease activity index, a similar index devised for patients with ulcerative colitis, and other commonly used laboratory indicators of disease activity have been studied in 50 patients with colonic inflammatory bowel disease undergoing routine colonoscopic assessment and compared with the histological extent and activity of disease. There was only poor correlation between the colonoscopic or histological findings and the indices of disease activity studied, showing that these are not reliable measures of disease activity or extent at the tissue level.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949241      PMCID: PMC1433178          DOI: 10.1136/gut.27.1.92

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES
Journal:  Br Med J       Date:  1964-01-11

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis.

Authors:  V Binder
Journal:  Scand J Gastroenterol       Date:  1970       Impact factor: 2.423

4.  Assessment of appropriate laboratory measurements to reflect the degree of activity of ulcerative colitis.

Authors:  L Descos; F André; C André; J Gillon; P Landais; J Fermanian
Journal:  Digestion       Date:  1983       Impact factor: 3.216

5.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis.

Authors:  J Powell-Tuck; D W Day; N A Buckell; J Wadsworth; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1982-06       Impact factor: 3.199

6.  Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.

Authors:  C Andre; L Descos; P Landais; J Fermanian
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

7.  Indium-111 autologous leucocyte scanning: comparison with radiology for imaging the colon in inflammatory bowel disease.

Authors:  S H Saverymuttu; A M Peters; H J Hodgson; V S Chadwick; J P Lavender
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-24

8.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  Indium-111-labeled autologous leukocytes in man.

Authors:  M L Thakur; J P Lavender; R N Arnot; D J Silvester; A W Segal
Journal:  J Nucl Med       Date:  1977-10       Impact factor: 10.057

10.  Relationship between clinical and laboratory parameters and length of lesion in Crohn's disease of small bowel.

Authors:  C Prantera; C Luzi; P Olivotto; S Levenstein; P Cerro; A Fanucci
Journal:  Dig Dis Sci       Date:  1984-12       Impact factor: 3.199

View more
  71 in total

1.  Technetium-99m hexamethyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease.

Authors:  E Lantto; K Järvi; I Krekelä; T Lantto; M Taavitsainen; H Vedenkangas; M Vorne
Journal:  Eur J Nucl Med       Date:  1992

2.  Quantification of autofluorescence imaging can accurately and objectively assess the severity of ulcerative colitis.

Authors:  Kentaro Moriichi; Mikihiro Fujiya; Masami Ijiri; Kazuyuki Tanaka; Aki Sakatani; Tatsuya Dokoshi; Shugo Fujibayashi; Katsuyoshi Ando; Yoshiki Nomura; Nobuhiro Ueno; Shin Kashima; Takuma Gotoh; Junpei Sasajima; Yuhei Inaba; Takahiro Ito; Hiroki Tanabe; Yusuke Saitoh; Yutaka Kohgo
Journal:  Int J Colorectal Dis       Date:  2015-08-13       Impact factor: 2.571

Review 3.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

4.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

5.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; S Tarui; M Okamoto
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

7.  The vasculitis in IBD is associated with the degree of inflammation.

Authors:  M Kruschewski; H J Buhr
Journal:  Dig Dis Sci       Date:  2009-03-07       Impact factor: 3.199

8.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

9.  Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.

Authors:  Michael Wagner; Christer G B Peterson; Peter Ridefelt; Per Sangfelt; Marie Carlson
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

10.  Immunomodulation does not alter histology in resected Crohn's disease.

Authors:  F A Frizelle; A Ing; R B Gearry; M Whitehead; I G Faragher; B Dobbs
Journal:  Tech Coloproctol       Date:  2009-09-23       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.